Publications in collaboration with researchers from Hospital Vall d'Hebron (10)

2025

  1. DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy

    Journal of Thoracic Oncology, Vol. 20, Núm. 3, pp. 345-365

2023

  1. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

2022

  1. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

2021

  1. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer

    Molecular Oncology, Vol. 15, Núm. 4, pp. 887-900

2020

  1. Epigenetic SmAd3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma

    Cancer Research, Vol. 80, Núm. 2, pp. 276-290

  2. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

    Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282

2019

  1. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging

    Thorax, Vol. 74, Núm. 4, pp. 371-379

  2. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2017

  1. Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3203-3213

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97